Beijing Tianxing Completes Hundreds of Millions RMB Series B Funding to Advance Integrated Clinical Solutions in Sports Medicine

VCBeat has learned at the earliest opportunity that,AsDomesticThe only one that can provideSports MedicineChina's Integrated Clinical SolutionsEnterpriseBeijing Star Biomedi Medical Device Co., Ltd. (hereinafter referred to as“Star Sports Medicine Co., Ltd.” recentlyAnnouncementCompleted hundreds of millions of yuanBRound of Financing，This round of financing was led byOrbiMedLead investor,3W PartnersCo-investment,Existing ShareholdersLegend Capital ContinuesAdditional Investment.Beijing Star IntroductionInvestment by renowned institutions, with follow-on investment from existing shareholders, demonstratesCompanyits exceptional strength and leading position in the industry.Dianshi Capital served as the exclusive financial advisor. 

Founded in 2017, Beijing Star Medical has always been committed to its mission as a guardian of healthy sports. After four years of intensive development, it has formed a comprehensive product strategy model offering integrated clinical solutions for implants, arthroscopic instruments, and sports medicine equipment. By building a robust product pipeline, the company has established a leading market position.

At this stage, Beijing Star Sports Medicine Co., Ltd. (Star) has established a comprehensive and multi-category product portfolio, mastering core technologies in sports medicine equipment, high-temperature injection molding, absorbable materials, and braiding. Its third-generation absorbable interference screws and absorbable anchors were the first to be launched in China, and Star remains the only domestic enterprise capable of providing absorbable products. Its all-suture anchors have even surpassed imported competitors, being the first to be launched and applied clinically in China. Furthermore, through collaborations with multiple hospitals, Star Academy has achieved deep integration of disciplinary talent advantages with industrial strengths.

Meanwhile, Beijing Star has partnered with dozens of domestic and international research and medical institutions to jointly build and refine a comprehensive ecosystem for the sports medicine industry chain. Currently, Star’s products are in clinical use at nearly 1,000 hospitals across 31 provinces and municipalities in China, including Beijing Jishuitan Hospital, Shanghai Sixth People’s Hospital, and Shenzhen Second People’s Hospital.

The proceeds from this round of financing will be used for product R&D and market expansion.

“We are delighted to have gained recognition from renowned professional investment firms such as OrbiMed, and we also thank our existing shareholders for their continued support,” said Dong Wenxing, Founder and CEO of Star Sports Medicine. “The new investors will not only bolster Star’s R&D investments and market expansion but also accelerate our overseas growth and strategic layout in the future direction of sports medicine.”

David Wang, Head of Greater China at OrbiMed, stated: “The sports medicine market in China is experiencing rapid growth, with a compound annual growth rate (CAGR) exceeding 25% over the past three years. As a leading enterprise in this field, Star Sports Medicine Co., Ltd. boasts a comprehensive product portfolio and maintains a leading position in commercialization progress. Furthermore, with an experienced management team, we are confident that under the leadership of its founder, the company will drive the development of China’s sports medicine sector and truly benefit patients.”

Zhou Quan, Managing Director at Legend Capital, stated: “As an early institutional investor in Star Medical, we are honored to have witnessed the company achieve highly challenging goals step by step with ‘Star Speed,’ which is attributable to the founder’s dedication and the team’s efficient execution capabilities. We firmly believe that under the leadership of Mr. Dong, the company will become a leading enterprise in sports medicine, both in China and globally.”

OrbiMed, founded in 1989, is the world’s largest investment firm dedicated exclusively to the healthcare and life sciences sector. Committed to identifying and supporting companies that advance human health, OrbiMed has specialized in global healthcare investments for over two decades. Its portfolio spans biopharmaceuticals, life sciences technologies, medical devices, healthcare services, and diagnostics, with investments covering all stages from early-stage startups and growth-phase companies to mature enterprises and post-IPO entities.

Legend Capital is an independent professional venture capital firm under Legend Holdings, with its core business focused on early-stage venture capital and growth-stage expansion investment. Currently, the total assets under management of its USD and RMB funds exceed RMB 60 billion, with a strategic focus on innovation and growth opportunities in China. As of 2021, Legend Capital had invested in more than 500 portfolio companies, among which over 90 have successfully listed or been quoted on domestic or overseas stock exchanges, and more than 70 have achieved exits through mergers and acquisitions. With the vision of “becoming the most valuable, respected, and internationally influential investment firm,” Legend Capital leverages capital and managerial support to foster enterprise innovation and growth. It plays an active role in promoting industrial progress and social development, striving to build desirable ventures with like-minded partners and share in their success.